Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.

Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6T1Z3, Canada.
Nature (Impact Factor: 42.35). 01/2009; 457(7229):599-602. DOI: 10.1038/nature07586
Source: PubMed

ABSTRACT BRAF and NRAS are common targets for somatic mutations in benign and malignant neoplasms that arise from melanocytes situated in epithelial structures, and lead to constitutive activation of the mitogen-activated protein (MAP) kinase pathway. However, BRAF and NRAS mutations are absent in a number of other melanocytic neoplasms in which the equivalent oncogenic events are currently unknown. Here we report frequent somatic mutations in the heterotrimeric G protein alpha-subunit, GNAQ, in blue naevi (83%) and ocular melanoma of the uvea (46%). The mutations occur exclusively in codon 209 in the Ras-like domain and result in constitutive activation, turning GNAQ into a dominant acting oncogene. Our results demonstrate an alternative route to MAP kinase activation in melanocytic neoplasia, providing new opportunities for therapeutic intervention.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Melanoma is an aggressive skin cancer that arises from melanocytes. Melanocytes produce the pigment melanin, which is pumped into the associated keratinocytes to act as a UV-protecting shield of the dividing cells in the basal layer of the epidermis and consequently results in darkened skin color and/or tanning. Benign lesions such as nevi result from an initial hyperprolifera-tion of melanocytes, which then undergo senes-cence. However, due to certain mutations, proliferation of these melanocytic cells may become deregulated and result in the formation of a melanoma – usually a radial, then a vertical growth phase and eventually a metastatic mela-noma. The challenge of diagnosing pigmented melanomas is mainly due to their similarity to dysplastic nevi [ 88 ] but also other pigmented lesions (e.g., pigmented basal cell carcinomas or pigmented seborrheic keratoses). There are also melanomas that display low pigment production and appear lighter in color (hypomelanotic) or pink or red (amelanotic). These melanomas are harder to diagnose as they are often either overlooked or mistaken for other types of skin disorders ; however, they are relatively rare [ 88 ]. Melanocytes are found throughout the body, including the epidermis, mucosa (e.g., mouth, rectum, vagina), and uvea, but also in the inner ear, brain, and lymph nodes. Cutaneous mela-noma, arising from melanocytes in the skin, is the most common form of melanoma, comprising
    Personalized Treatment Options in Dermatology, Edited by Bieber T & Nestle F, 03/2015: chapter 2: pages 7-27; Springer-Verlag Berlin Heidelberg., ISBN: 978-3-662-45839-6
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Malignant melanoma is an aggressive cutaneous neoplasm whose incidence has continued to increase worldwide. Currently, histopathologic examination of specimens is the gold standard for the diagnosis and categorization of melanoma. Cytogenetic analysis represents a powerful, and currently underused, adjunct to traditional histologic examination in distinguishing nevi and melanomas. Chromosomal studies have shown that malignant melanomas often contain multiple chromosomal alterations, most commonly of chromosomes 1, 6, 7, 9, 10 and 11. These chromosomes often include genes within the MAPK molecular pathway, which is involved in the development and progression of melanoma. Fluorescence in situ hybridization (FISH) can detect a number of recurrent anomalies, and commercially available kits for melanoma detection have been devised. The utility of cytogenetics in melanocytic lesions at certain anatomic sites has been evaluated, including acral lesions, uveal lesions, and lymph node metastases. Recurring cytogenetic anomalies have been defined in various challenging histologic subtypes, such as desmoplastic melanomas and Spitzoid lesions. Cytogenetic analysis may also be used to provide supplementary information in prognostication, particularly in uveal melanomas. We provide a brief review of the molecular pathways found in melanoma and a summary of what is known and remains unknown regarding cytogenetic aberrations associated with malignant melanoma. Keywords: nevus, nodal nevus, blue nevus, cutaneous melanoma, desmoplastic melanoma, uveal melanoma, blue nevus-like melanoma, cytogenetics, FISH, fluorescence in situ hybridization
    Journal of the Association of Genetic Technologists 10/2014; 40(4):209-218.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The incorporation of individualized molecular therapeutics into routine clinical practice for both non-small cell lung cancer (NSCLC) and melanoma are amongst the most significant advances of the last decades in medical oncology. In NSCLC activating somatic mutations in exons encoding the tyrosine kinase domain of the Epidermal Growth Factor Receptor (EGFR) gene have been found to be predictive of a response to treatment with tyrosine kinase inhibitors (TKI), erlotinib or gefitinib. More recently the EML4-ALK fusion gene which occurs in 3-5% of NSCLC has been found to predict sensitivity to crizotinib an inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. Similarly in melanoma, 50% of cases have BRAF mutations in exon 15 mostly V600E and these cases are sensitive to the BRAF inhibitors vemurafenib or dabrafenib. In a Phase III study of advanced melanoma cases with this mutation vemurafenib improved survival from 64% to 84% at 6 months, when compared with dacarbazine. In both NSCLC and melanoma clinical benefit is not obtained in patients without these genomic changes, and moreover in the case of vemurafenib the therapy may theoretically induce proliferation of cases of melanoma without BRAF mutations. An emerging clinical challenge is that of acquired resistance after initial responses to targeted therapeutics. Resistance to the TKI's in NSCLC is most frequently due to acquisition of secondary mutations within the tyrosine kinase of the EGFR or alternatively activation of alternative tyrosine kinases such as C-MET. Mechanisms of drug resistance in melanoma to vemurafenib do not involve mutations in BRAF itself but are associated with a variety of molecular changes including RAF1 or COT gene over expression, activating mutations in RAS or increased activation of the receptor tyrosine kinase PDGFRβ. Importantly these data support introducing re-biopsy of tumors at progression to continue to personalize the choice of therapy throughout the patient's disease course.
    Journal of personalized medicine. 01/2012; 2(2):35-49.

Full-text (2 Sources)

Available from
Jul 21, 2014